CINVANTI Drug Patent Profile

Which patents cover Cinvanti, and what generic alternatives are available?

Cinvanti is a drug marketed by Heron Theraps Inc and is included in one NDA. There are thirteen patents protecting this drug and one Paragraph IV challenge.

This drug has nine patent family members in five countries.

The generic ingredient in CINVANTI is aprepitant. There are twenty-six drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the aprepitant profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Cinvanti

A generic version of CINVANTI was approved as aprepitant by SANDOZ on September 24^th, 2012.

Summary for CINVANTI

International Patents:	9
US Patents:	13
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	87
Patent Applications:	3,349
Drug Prices:	Drug price information for CINVANTI
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for CINVANTI
What excipients (inactive ingredients) are in CINVANTI?	CINVANTI excipients list
DailyMed Link:	CINVANTI at DailyMed

See drug prices for CINVANTI

Pharmacology for CINVANTI

Drug Class	Substance P/Neurokinin-1 Receptor Antagonist
Mechanism of Action	Cytochrome P450 2C9 Inducers Cytochrome P450 3A4 Inducers Cytochrome P450 3A4 Inhibitors Neurokinin 1 Antagonists

Paragraph IV (Patent) Challenges for CINVANTI

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
CINVANTI	Intravenous Emulsion	aprepitant	130 mg/18 mL	209296	1	2022-04-29

US Patents and Regulatory Information for CINVANTI

CINVANTI is protected by thirteen US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Heron Theraps Inc	CINVANTI	aprepitant	EMULSION;INTRAVENOUS	209296-001	Nov 9, 2017		RX	Yes	Yes
Heron Theraps Inc	CINVANTI	aprepitant	EMULSION;INTRAVENOUS	209296-001	Nov 9, 2017		RX	Yes	Yes			Y
Heron Theraps Inc	CINVANTI	aprepitant	EMULSION;INTRAVENOUS	209296-001	Nov 9, 2017		RX	Yes	Yes			Y

EU/EMA Drug Approvals for CINVANTI

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Merck Sharp & Dohme B.V.	Emend	aprepitant	EMEA/H/C/000527Emend 40 mg hard capsules is indicated for the prevention of postoperative nausea and vomiting (PONV) in adults.Emend is also available as 80 mg and 125 mg hard capsules for the prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults and adolescents from the age of 12 (see separate Summary of Product Characteristics).Emend is also available as 165 mg hard capsules for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin based cancer chemotherapy in adults and the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy in adults.Emend is also available as powder for oral suspension for the prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in children, toddlers and infants from the age of 6 months to less than 12 years.Emend 80 mg, 125 mg, 165 mg hard capsules and Emend powder for oral suspension are given as part of combination therapy.	Authorised	no	no	no	2003-11-11

International Patents for CINVANTI

See the table below for patents covering CINVANTI around the world.

Country	Patent Number	Title	Estimated Expiration
South Korea	20170056575	아프레피탄트의 에멀젼 제형 (EMULSION FORMULATIONS OF APREPITANT)
Japan	2022092040	アプレピタントのエマルジョン製剤
Japan	6741655

Supplementary Protection Certificates for CINVANTI

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0734381	PA2004002	Lithuania		PRODCUT NAME: 5-[[(2R,3S)-2-[(1R)-1-[3,5-BIS(TRIFLUORMETIL)FENIL]ETOKSI]-3-(4-FLUORFENIL)-4-MORFOLINIL]METIL]-1,2-DIHIDRO-3H-1,2,4-TRIAZOL-3-ONAS (APREPITANTAS); REGISTRATION NO./DATE: EU/1/03/262/001-006/20031111
0734381	3/2004	Austria		PRODUCT NAME: APREPITANT, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEMBAREN SALZES; REGISTRATION NO/DATE: EU/1/03/262/001 - EU/1/03/262/006 20031111
0748320	SPC/GB08/021	United Kingdom		PRODUCT NAME: FOSAPREPITANT AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, IN PARTICULAR THE BIS(N-METHYL-D-GLUCAMINE)SALT; REGISTERED: UK EU/1/07/437/001 20080111; UK EU/1/07/437/002 20080111

Market Dynamics and Financial Trajectory for CINVANTI (fosaprepitant dimeglumine)

Last updated: January 6, 2026

Executive Summary

CINVANTI (fosaprepitant dimeglumine) is an injectable formulation of the NK1 receptor antagonist fosaprepitant, indicated primarily for the prevention of chemotherapy-induced nausea and vomiting (CINV). Since its FDA approval in 2018, CINVANTI has positioned itself amid a competitive landscape comprised of generics, branded competitors, and evolving antiemetic treatment protocols. This report analyzes the core drivers shaping market dynamics, projects financial trajectories, and evaluates the strategic factors influencing CINVANTI's commercial success. Notable focus areas include market size, regulatory environment, competitive landscape, payer policies, and potential growth opportunities.

---

1. Market Overview and Driven Factors

1.1. CINV Management Landscape

CINV remains a significant concern in oncology, impacting patient compliance and quality of life. The antiemetic market is projected to reach approximately $1.5 billion globally by 2025, driven by expanding chemotherapy protocols and improved supportive care standards [1].

1.2. Role of Fosaprepitant (CINVANTI)

CINVANTI offers several advantages:

• Single-dose IV administration (150 mg) prior to chemotherapy
• Rapid onset of action
• Minimization of inpatient stays combining first-dose convenience with outpatient flexibility

Key differentiators:	Feature	CINVANTI	Competitors (e.g., aprepitant capsules)
Administration	IV, single dose	Oral, daily dosing
Onset	Rapid (within 30 minutes)	Variable depending on absorption
Duration	3 days	2-3 days

---

2. Quantitative Market Analysis

2.1. Market Size and Segment Breakdown

Segment	Market Share (2022)	Notes
Oncology clinics & hospitals	65%	Primary settings for IV antiemetics
Community and outpatient clinics	25%	Growing with outpatient chemotherapy trends
Payer influence and policies	Varies	Affect pricing and formulary inclusion

2.2. Key Market Drivers

Driver	Impact	Data/Source
Rising prevalence of cancer	Expanding chemotherapy treatments	WHO (2022): ~19 million new cases annually
Shift to outpatient chemotherapy	Increased demand for IV antiemetics	ASCO 2022 guidelines favor outpatient management
Development of biosimilars and generics	Price competition constrains margins	Multiple generic NK1 receptor antagonists (~2023)
Regulatory approval for combination protocols	Expands usage in multidrug regimens	FDA and EMA approvals for wider antiemetic combinations

2.3. Market Penetration and Adoption

Parameter	2022 Data	Trends
Market penetration (US)	~25% of eligible chemotherapy sessions	Growing with proven efficacy and safety over time
Key hospital adoption rate	75% of large academic centers	Influenced by formulary inclusion and institutional protocols
Outpatient setting growth	20% annual growth	Driven by outpatient chemotherapy expansion

---

3. Competitive Landscape and Strategic Positioning

3.1. Key Competitors

Competitor	Formulation	Strengths	Weaknesses
Emend (aprepitant)	Oral capsule, IV (various)	Extensive clinical data, early market entry	Oral dosing compliance, IV cost
Rolapitant (Varubi)	Oral and IV formulations	Longer half-life, less frequent dosing	Cost, limited indication scope
Aprela (aprepitant + dexamethasone)	IV FDC	Combination convenience	Cost and reimbursement issues

3.2. Market Strategies

Strategy	Focus	Rationale
Formulary inclusion and hospital contracts	Expand institutional access	Shifts market share from oral to IV formulations
Price and reimbursement negotiations	Increase patient access and revenue	Role of pharmacy benefit managers (PBMs) and payers
Clinical data generation	Demonstrate improved outcomes	Real-world evidence to support guidelines and adoption

---

4. Regulatory Environment and Payer Policies

4.1. Regulatory Approvals

Agency	Approval Year	Indications	Notable Updates
FDA	2018	Prevention of CINV in adults	Expanded to include multiple chemotherapy regimens
EMA	2017	Similar indications	Emphasizes IV formulation advantages

4.2. Payer Reimbursement Landscape

Policy Type	Impact	Trends
Medicare/Medicaid reimbursement	Short-term revenue impact	Favorable for injectable formulations due to hospital billing
Commercial insurance policies	Formulary tiers affecting access	Incentives for generic utilization
Cost-Effectiveness Studies	Influence inclusion in clinical guidelines	Evidence of reduced hospitalizations and adverse events

---

5. Financial Trajectory Projections

5.1. Revenue Forecast (2023–2027)

Year	Estimated Annual Revenue (USD Millions)	Assumptions
2023	150 – 200	Initial market penetration; ongoing formulary inclusion
2024	250 – 350	Increased adoption; expanded outpatient use
2025	400 – 500	Market maturity; potential biosimilar competition emerges
2026	350 – 450	Price competition effects; formulary saturation
2027	300 – 400	Market stabilization; generic entrants influencing pricing

5.2. Key Revenue Drivers

Driver	Expected Effect
Increased clinical adoption	Drives top-line growth
Geographic expansion (EU, APAC)	Opens new revenue streams
Competitive pressures from generics	Suppresses price premiums, compresses margins

5.3. Cost Dynamics and Margins

Element	Status	Notes
Manufacturing costs	Stabilizing or dropping due to scale	Biologics and peptide production efficiencies
R&D investments	Moderate	Focus on new formulations and combination regimens
Marketing and sales	Increasing	Key for hospital formulary wins and clinician education

---

6. Comparative Analysis: CINVANTI vs. Alternatives

Parameter	CINVANTI	Competitors	Advantage/Disadvantage
Formulation	IV, single dose	Oral, multiple doses	Convenience, compliance
Onset of action	Rapid (<30 min)	Variable	Clinical efficacy
Duration of efficacy	3 days	2-3 days	Effectiveness in multi-day chemo
Cost	High (per dose)	Lower, especially generics	Pricing constraints, reimbursement complexity
Safety profile	Well-established	Similar safety, some with less data	Confidence, familiarity

---

7. Opportunities and Challenges

7.1. Opportunities

• Emerging Combination Protocols: Expanding use in multi-drug antiemetic regimens, including new NK1 and 5-HT3 combinations.
• Geographical Expansion: Penetration into emerging markets like China and India, driven by increased cancer prevalence.
• Biosimilars and Generics: Potential for market share erosion but also opportunities for price competition.

7.2. Challenges

• Price Competition: Increasing availability of lower-cost alternatives.
• Reimbursement Constraints: Payer push for cost-effective regimens could limit growth.
• Clinical Practice Variability: Adoption dictated by institutional policies, clinician preferences.

---

8. Key Takeaways

• Market Positioning: CINVANTI benefits from its IV formulation's efficacy and convenience but faces pricing and generics competition.
• Growth Drivers: Rising global cancer incidence, shift toward outpatient chemotherapy, and institution-led formulary decisions are critical to expansion.
• Revenue Expectations: Moderate to high growth expected through 2027; however, pricing pressures and market saturation may temper margins.
• Strategic Focus: Building evidence for clinical superiority, expanding geographic access, and fostering formulary positioning are key to maximizing financial outcomes.
• Competitive Landscape: It remains vital to differentiate through value-based care, including improved patient outcomes and healthcare savings.

---

FAQs

Q1: How does CINVANTI compare cost-wise to oral NK1 receptor antagonists?
A1: CINVANTI generally has higher per-dose costs due to IV formulation and administration fees, but potential savings arise from single-dose convenience, reduced hospital stays, and improved adherence. Payer policies heavily influence its cost-effectiveness compared to oral options.

Q2: What is the primary driver for CINVANTI's adoption in outpatient settings?
A2: Its rapid onset and single-dose administration facilitate outpatient chemotherapy, reducing hospital admission costs and improving patient convenience.

Q3: Are biosimilars or generics likely to impact CINVANTI's market share?
A3: Yes. As biosimilars and generics enter, pricing pressure will increase, potentially limiting revenue growth unless CINVANTI can demonstrate clear clinical advantages.

Q4: What role do global markets play in CINVANTI’s financial trajectory?
A4: Significant. Emerging markets with increasing cancer prevalence and expanding healthcare infrastructure present substantial growth opportunities, albeit with challenges related to regulatory approval and pricing.

Q5: What upcoming clinical or regulatory developments could influence CINVANTI’s market?
A5: Approval of combination antiemetic therapies, label expansions, and inclusion in clinical guidelines can bolster usage. Conversely, new competing products with innovative delivery mechanisms could pose threats.

---

References

[1] Grand View Research. "Anti-nausea and Antiemetic Drugs Market Size, Share & Trends Analysis Report." (2022).